Concepedia

Publication | Open Access

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

DOIFull Paper Access

655

Citations

30

References

2019

Year

Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou, Ajay K. Nooka, Andrew J. Yee, Carol Ann Huff, Philippe Moreau, David Dingli, Craig E. Cole, Sagar Lonial,
New England Journal of Medicine

Abstract

Selinexor-dexamethasone resulted in objective treatment responses in patients with myeloma refractory to currently available therapies. (Funded by Karyopharm Therapeutics; STORM ClinicalTrials.gov number, NCT02336815.).

References

YearCitations

Page 1